Innoviva, Inc.
Innoviva, Inc. (INVA): 17 pipeline candidates · 5 upcoming catalysts · ~52 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
52.1 months
15% dilution
Lead: Approved
17 candidates
5 upcoming, next in ~1625d
N/A
A transparent, data-derived signal for Innoviva, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$603.1M
Quarterly Burn
$37.7M
Runway
52.1 mo
Revenue
$98.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (17 candidates)
| Drug | Phase |
|---|---|
| Angiotensin-II | Phase 4 |
| ANORO ELLIPTA | Approved |
| ANORO® ELLIPTA® | Approved |
| GIAPREZA | Approved |
| GIAPREZA® | Approved |
| nuzolvence | Approved |
| RELVAR/BREO ELLIPTA | Approved |
| RELVAR®/BREO® ELLIPTA® | Approved |
| Sulbactam 20mg/kg-Durlobactam 20mg/kg | Phase 1 |
| Sulbactam 25mg/kg -Durlobactam 25mg/kg | Phase 1 |
Showing 10 of 17 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
284
Total value held
$1.80B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 11,307,845 | $263.5M |
| vanguard capital management llc | 6,283,162 | $146.4M |
| dimensional fund advisors lp | 4,436,427 | $103.4M |
| vanguard portfolio management llc | 4,224,951 | $98.4M |
| renaissance technologies llc | 4,055,632 | $94.5M |
| state street corp | 3,060,377 | $71.3M |
| millennium management llc | 2,279,451 | $53.1M |
| sarissa capital management lp | 2,130,950 | $49.7M |
| systematic financial management lp | 2,024,082 | $47.2M |
| geode capital management, llc | 1,929,718 | $45.0M |
Showing top 10 of 284 institutional holders of Innoviva, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Innoviva, Inc.'s pipeline?
Innoviva, Inc. (INVA) has 17 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Innoviva, Inc.'s lead drug candidate?
Innoviva, Inc.'s most advanced tracked candidate is Angiotensin-II (Phase 4) for Vasodilatory Shock.
What is Innoviva, Inc.'s next catalyst?
Innoviva, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ANORO ELLIPTA" — expected November 29, 2030.
What is Innoviva, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Innoviva, Inc. has approximately 52.1 months of cash runway.
What is Innoviva, Inc.'s market capitalization?
Innoviva, Inc.'s market capitalization is approximately $1.7B.
Get the full picture on Innoviva, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.